Controlling the process of gene regulation could help treat a wide range of human diseases by silencing portions of the genetic code at the root of the problem. Now investigators may have tapped into a way to create an even more powerful class of miRNA inhibitors and enhancers.
With an increasing reliance on nanoparticles to deliver intravenous drug treatments and serve as imaging agents, how do you make sure they are powerful enough to reach their target? The answer: math.
Mersana Therapeutics thinks it's developed the next generation of cancer treatment drugs. Called antibody-drug conjugates (ADCs), Mersana has developed two compounds that connect small molecule anti-cancer drugs and tumor-targeting antibodies in a single package.
InCube Labs, a California incubator for medical device, drug delivery and biotech companies, has raised $30 million in public and private financing so far for its expansion into San Antonio, TX.
For patients recovering from eye surgery, there could be a new way to get anesthetics and other drugs into the eye through the cornea: bandage contact lenses.
Icon Bioscience's preclinical eye injection compound for a rare and aggressive form of childhood eye cancer won the FDA's orphan drug designation recently.
West Coast biotech vets have joined forces to solve one of the thorniest delivery issues in the industry--ushering RNA drugs into cells. Their startup has nailed down $18 million in a Series A round of financing and grabbed a license to delivery tech from the University of California, San Diego.
FierceDrugDelivery will be taking a brief break over the holidays, but we will be back Jan. 2.
Ocular Therapeutix' travoprost eye delivery system, OTX-TP2, released drug consistently over two months and cut pressure inside the eye in people with glaucoma and ocular hypertension.
Fuse Science has created a patchless delivery technology that could allow drugs to be rolled on as simply as an underarm deodorant, with success in tests for drugs from caffeine to insulin.